Intended for healthcare professionals


Influenza drug to undergo “fast track” assessment by NICE

BMJ 1999; 319 doi: (Published 14 August 1999) Cite this as: BMJ 1999;319:400
  1. Judy Jones
  1. BMJ

    The influenza drug zanamivir (Relenza) will undergo “fast track” appraisal by the new National Institute for Clinical Excellence (NICE), which will recommend which treatments should be available on the NHS in England and Wales. Zanamivir is said to moderate the symptoms of flu and shorten bouts of the illness.

    Professor Sir Michael Rawlins, the institute's chairman, said last week that he hopes to publish recommendations on the use of the drug this autumn. Thereafter, the …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription